Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing

• Published in: Frontiers in oncology Vol. 14; p. 1365330
• Main Authors: Zhou, Jianbiao, Chng, Wee-Joo
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.04.2024
• Subjects: acute myeloid leukemia (AML); bone marrow microenvironment; immunotherapy; intratumoral heterogeneity; leukemia stem cell (LSC); Oncology; single cell RNA-sequencing (scRNA-seq); leukemia stem cell (LSC); bone marrow microenvironment; immunotherapy; single cell RNA-sequencing (scRNA-seq); intratumoral heterogeneity; acute myeloid leukemia (AML); novel therapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1365330

Acute myeloid leukemia (AML) is a complex and heterogeneous group of aggressive hematopoietic stem cell disease. The presence of diverse and functionally distinct populations of leukemia cells within the same patient’s bone marrow or blood poses a significant challenge in diagnosing and treating AML. A substantial proportion of AML patients demonstrate resistance to induction chemotherapy and a grim prognosis upon relapse. The rapid advance in next generation sequencing technologies, such as single-cell RNA-sequencing (scRNA-seq), has revolutionized our understanding of AML pathogenesis by enabling high-resolution interrogation of the cellular heterogeneity in the AML ecosystem, and their transcriptional signatures at a single-cell level. New studies have successfully characterized the inextricably intertwined interactions among AML cells, immune cells and bone marrow microenvironment and their contributions to the AML development, therapeutic resistance and relapse. These findings have deepened and broadened our understanding the complexity and heterogeneity of AML, which are difficult to detect with bulk RNA-seq. This review encapsulates the burgeoning body of knowledge generated through scRNA-seq, providing the novel insights and discoveries it has unveiled in AML biology. Furthermore, we discuss the potential implications of scRNA-seq in therapeutic opportunities, focusing on immunotherapy. Finally, we highlight the current limitations and future direction of scRNA-seq in the field.